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http:WHAT THIS PAPER ADDS
Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease. This phase I clinical study shows
that intramuscular injection of plasmid DNA (pUDK-HGF) expressing human hepatocyte growth factor (HGF) to
patients with critical limb ischemia (CLI) is safe and well tolerated. Pain and ulcer are markedly improved.Objective: Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease and a major unmet
public health care need. This phase I clinical study was performed to assess the safety and preliminary efﬁcacy of
naked plasmid DNA (pUDK-HGF) expressing human hepatocyte growth factor (HGF) in patients with critical limb
ischemia (CLI).
Design: Twenty-one patients with CLI were enrolled and randomly divided into four dose groups (4e16 mg) to
receive local injection of pUDK-HGF into ischemic calf and/or thigh muscles twice on days 1 and 15. Safety,
including adverse events and physiological parameters, and preliminary efﬁcacy, including pain severity score
(VAS), ulcer size, transcutaneous oxygen pressure (TcPO2), and ankle brachial index (ABI), were evaluated
throughout a 3 month follow up period.
Results: All doses of pUDK-HGF were well tolerated by the patients. None of the adverse effects was considered
to be related to pUDK-HGF injection. Two signiﬁcant clinical results were observed after pUDK-HGF
administration. The mean VAS value of all patients decreased from 4.52 at baseline to 0.30 (p < .01), and pain
had disappeared in 14 out of 17 evaluable patients by day 91. Two of four ulcers had completely healed, with the
other two patients having more than 25% ulcer size reduction in the long axis diameter. Of ﬁve patients with
gangrene, one gangrenous wound had healed completely and two patients showed marked size reduction by day
91. The mean hemodynamic parameters (ABI, TcPO2) were also improved.
Conclusion: Intramuscular injection of pUDK-HGF is safe, and may provide symptomatic relief for CLI patients. A
larger, randomized, double blinded phase II trial will provide more information on safety and efﬁcacy.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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//dx.doi.org/10.1016/j.ejvs.2015.05.007lower extremities. At present, the standard therapy for CLI is
revascularization either by endovascular techniques or open
bypass surgery. Despite the success of these treatments, they
remain associated with substantial morbidity and mortality.
There is a need for effectivemedicalmanagement for CLI, and
in particular less invasive treatment.1e4
Hepatocyte growth factor (HGF) has been shown to pro-
mote endothelial cell proliferation and angiogenesis to
induce collateral formation in preclinical models of periph-
eral arterial disease.5e9 Based on these HGF properties,
several early clinical trials using naked plasmid DNA
expressing HGF were performed in the USA and Japan. These
trials showed promising results, with no serious adverse
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scale score and ulcer size.10e17 The main difference between
these clinical trials was that some used plasmid DNA
expressing single HGF,10e15 and others used plasmid DNA co-
expressing two isomers of HGF, one consisting of 728 amino
acids (known as HGF, or HGF728) and the other consisting of
723 amino acids (known as deleted HGF, or HGF723).
16e18
Two plasmids (pCK-HGF-X7 and pUDK-HGF) expressing
HGF have been used in a clinical trial in China. pCK-HGF-X7
expresses two isoforms of HGF (HGF728 and HGF723), and
has completed phase I clinical trials. Gu reported phase I
clinical trial results of pCK-HGF-X7 in patients with critical
limb ischemia (CLI). The safety and preliminary efﬁcacy
including pain reduction, decreased VAS, and increased ABI
or TcPO2 value, support subsequent phase II randomized
controlled trials.17
pUDK-HGF is a simple plasmid DNA expressing HGF only
consisting of 728 amino acids. Pre-clinical studies have
indicated therapeutic potential in both rat and dog hind
limb ischemia models.19e23 Intramuscular injection of
pUDK-HGF around the ligation position of a rat femoral
artery ligation hindlimb ischemia model resulted in efﬁcient
gene transfer and strong HGF expression in local skeletal
muscle tissue. At day 10 after injection, the ischemic limb
muscles were removed and stained with HE. Signiﬁcantly
increased capillary density was found in the ischemic tissue,
compared with that of empty plasmid pUDK injected ani-
mals. In dog hindlimb ischemia models (complete or part
femoral artery ligation), after intramuscular injection of
pUDK-HGF in ischemic hindlimbs, signiﬁcant augmentation
of the collateral vessel from the origin stem artery was
observed by angiography at days 30 and 90, and improved
blood ﬂow was also observed at days 30 and 90 using
Doppler ﬂow wire. In addition, no toxic effects of pUDK-HGF
were found in single or multiple dose toxicology studies in
rats and dogs. All these results support further clinical trials.
This paper reports the results of a phase I clinical trial,
including safety and preliminary efﬁcacy of intramuscular
injection of pUDK-HGF into the limbs of patients with CLI.Table 1. Dose groups and injection regimen.
Cohort Case n Total dose (mg) Injection sitesPATIENTS AND METHODS
pUDK-HGF plasmid
The recombinant pUDK-HGF plasmid consists of a cDNA
fragment of human HGF (EcoRI/NotI, 2.2 kbp) inserted into
a pUDK vector driven under a human cytomegalovirus
promoter.19 The construct does not have DNA sequence
homology to the human genome (except the HGF insert),
and the vector sequences do not have known oncogenic
potential. pUDK-HGF was provided by Humanwell Health-
care (Group) Co. Ltd, Wuhan, China. The product was sup-
plied in a sterile glass vial at a concentration of 2 mg/mL in
the formulation solution, and stored at 4e8 C.Day 0 Day 15
I 3 4 8 (2 mg) 8 (2 mg)
II 6 8 16 (4 mg) 16 (4 mg)
III 6 12 24 (6 mg) 24 (6 mg)
IV 6 16 32 (8 mg) 32 (8 mg)Study design
This was a prospective, open label, dose escalation, single
center study designed to assess the safety and tolerability ofintramuscular injection of pUDK-HGF in patients with CLI.
The study design was similar to a previous study by Gu
et al.17 Brieﬂy, 21 patients were enrolled and randomly
divided into four dose groups to receive 4, 8, 12, or 16 mg
of pUDK-HGF. Each patient received local intramuscular
injections in calf and/or thigh muscles twice, the ﬁrst in-
jection of half of the dose of pUDK-HGF on day 1, with the
second half at day 15 (Table 1). The ﬁrst injection site, based
on the vascular disease anatomy, was 2 cm above the start
of the stenosis or occlusion, then multiple site injections
were regularly distributed along the course of the blood
vessel a minimum of 2 cm apart. Each injection contained
0.25 mg pUDK-HGF in 0.5 mL 0.9% normal saline. Safety,
including adverse events and physiological parameters, and
preliminary efﬁcacy, including pain severity score (VAS),
ulcer size and ABI, and TCPO2, were evaluated at baseline
and throughout a 3 month follow up period.
The study was approved by the ethics committee at
Xuanwu Hospital of Capital Medical University and Chinese
Food and Drug Administration. All patients provided written
informed consent to participate in the study.
Patient population, enrollment, and exclusion criteria
Patients aged 20e80 years with ischemic lower limb arterial
disease (Rutherford Categories 4e6), diagnosed by angiog-
raphy, were enrolled. Patients were also required to have
normal laboratoryexaminations including hemoglobin, platelet
count, fasting glucose, glycosylated hemoglobin A1c, aspartate
aminotransferase and/or alanine aminotransferase.17
Major exclusion criteria included patients who had a poor
vascular disease prognosis and who, in the investigator’s
opinion, would require amputation within 3 months; pa-
tients who had signiﬁcant aortoiliac occlusive disease or
advanced clinical manifestations of severe CLI with more
than 70% abdominal aortic and iliac artery occlusion/nar-
rowing; and patients who had undergone a successful
revascularization procedure less than 12 weeks prior to
study entry, or vascular reconstruction failure within 4
weeks of the start of the study. Patients were also excluded
if they had stage 3 or higher retinopathy, malignant tumor
or suspected malignant tumor by screening tests, resistant
hypertension (systolic blood pressure >200 mmHg or dia-
stolic blood pressure >115 mmHg), or any type of infection
(e.g. hepatitis B, C, AIDS, or syphilis).
Patient follow up and safety assessment
Baseline assessments were obtained as a reference before
the ﬁrst injection. Follow up assessments were obtained
throughout the subsequent 3 month period.
Table 2. Patient characteristics.
Cohort Case
no.
Age/
sex
Disease Stage Endovascular
surgery history
I 101 45/M TAO 5 PTA
102 73/M DASO 4 Artery bypass, PTA
103 67/M DASO 4
II 104 34/M ASO 4
105 79/F ASO 5
106 43/M TAO 5
107 70/M ASO 5 Artery bypass,
stent implantation
108 64/M DASO 5 Amputation
below knee
109 57/M TAO 5 PTA
III 110 34/M TAO 5
111 77/M DASO 4 Artery bypass
112 71/F ASO 4 Stent implantation
113 41/M TAO 5
114 24/M TAO 4 Artery bypass
115 70/F DASO 5 Amputation
below knee
IV 116 54/M ASO 4 Stent implantation
117 78/F DASO 5
118 75/M ASO 4 Catheter directed
thrombolysis
119 50/M ASO 4 Varicose vein surgery
120 58/M ASO 4
121 20/M TAO 4
ASO ¼ arteriosclerosis obliterans; PTA ¼ percutaneous
transluminal angioplasty; TAO ¼ thromboangiitis obliterans
(Buerger disease).
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cording to NCI Common Terminology Criteria for Adverse
Events v3.0, and changes from baseline in physical and
laboratory examinations, chest X-ray, electrocardiogram,
and cancer and retinopathy screening.
The serum HGF protein level was analyzed using a vali-
dated Human HGF Quantikine ELISA kit (R&D Systems,
Minneapolis, MN, USA) at baseline (just before the ﬁrstTable 3. Adverse events occurring after pUDK-HGF injection.
Cohort Case no. Adverse events
I 103 Abnormal presence protein urine
II 105 Abnormal white blood cell count
Abnormal neutrophil granulocyte pe
Hematuria
Presence of white cell in urine
II 107 Abnormal white blood cell count
Abnormal neutrophil granulocyte pe
Monocyte percentage abnormal
II 109 ALT abnormal
IV 116 ALT abnormal
IV 117 Acute heart insufﬁciency
Pulmonary infection
Acute renal insufﬁciency
Infectious toxic shock
Gastrointestinal hemorrhage
IV 118 Hematuria
IV 121 Double lower extremity purpurainjection) and at days 8, 15 (before the second injection),
21, and 59. The linearity between OD and HGF concentra-
tion was determined from 125.00 to 8,000.00 pg/mL. The
copy number of the plasmid DNA was measured using a real
time PCR method and performed using MJ Opticon 2
Chromo 4 (BioRad) in 96-well plates.24 Primers for pUDK-
HGF sequence were chosen according to the speciﬁcity
and maximal Rn value. The forward primer (50-ATGCAT-
GACCTGCAATGGG-30) and the reverse primer (50-GAGTA-
TAGCACCATGGCCTCG-30) were used. The plasmid
concentration was determined using a ﬂuorometer and the
corresponding copy number was calculated by the following
equation: copy number ¼ (6.02  1023 copy/mol)  DNA
amount (g)/[DNA length (bp)  660 (g/mol/bp)]. The lower
limit of quantitation for pUDK-HGF in whole blood was 100
copies per 1 mg of genomic DNA.
Anti-HGF antibody was detected using an ELISA method
at baseline (just before the ﬁrst injection) and days 15
(before the second injection), 28, 59, and 91. The 96-well
microtiter plates (Thermo Labsystems, Franklin, MA) were
coated with HGF for 16 hours at 4 C, and 1:10 diluted
serum samples were added and incubated for 2 hours at
room temperature. HRP-goat anti human IgG (100 mL;
Sigma, 1:80,000) was used for determination of anti-HGF
antibody.Efﬁcacy assessment
Pain assessment was evaluated using a self administered
visual analog scale (VAS, 0e10) at baseline and at days 8,
15, 21, 28, 59, and 91 after the ﬁrst injection.
Transcutaneous oximetry (TcPO2) measurement was
monitored for 30 minutes in the supine body position at
baseline and at days 28, 59, and 91.
Ankle brachial index (ABI) was measured at baseline, and
at days 28, 59, and 91. Resting ankle systolic pressure in the
dorsalis pedis and posterior tibial arteries, and resting sys-
tolic brachial blood pressure were measured (systolic at
rest) using the toe plethysmographic wave or Doppler waveGrade Relationship with drug
Mild Unrelated
Mild Unrelated
rcentage Mild Unrelated
Mild Unrelated
Mild Unrelated
Mild Unrelated
rcentage Mild Unrelated
Mild Unrelated
Mild Unrelated
Mild Unrelated
Life-threatening Unrelated
Life-threatening Unrelated
Life-threatening Unrelated
Life-threatening Unrelated
Life-threatening Unrelated
Mild Unrelated
Mild Unrelated
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59, and 91.
All ulcers and gangrene present at baseline and any new
ulcer and gangrene developing during the study period
were digitally recorded. The ulcer size was measured using
calipers at baseline and at days 15, 28, 59, and 91.Statistical analysis
Continuous variables (ABI, VAS) are expressed as
median  SD and interquartile ranges; a Student paired t
test was used for comparison of differences between
baseline and after injection. Categorical variables are
expressed as frequencies or percentages and analyzed by
Fisher’s exact test. Statistical analysis was performed using
SAS, version 9.1.3, with p < .05 considered to be statisti-
cally signiﬁcant.RESULTS
Patient characteristics
Twenty-one patients with lower limb ischemia were
enrolled into this study and randomly divided into four dose
groups. Patient demographics were not different between
the groups as shown in Table 2. The median age was 56.4
years (range 20e78) and 81% were male. Surgical revas-
cularization and endovascular therapy had been performed
in 57% of subjects.
Four patients discontinued the study according to exit
criteria. Two patients (Cases 105 and 112) withdrew consent
at day 59 because of progression of non-healing ulcers and
the need for amputation. One patient (Case 117) died at
day 9 because of heart failure, but this death was consid-
ered to be unrelated to pUDK-HGF treatment. The fourth
patient (Case 121) withdrew consent at day 59 because of
undergoing bypass revascularization.0 8 15 21 59
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Figure 1. Concentration of HGF protein in serum after intramus-
cular pUDK-HGF injection.Safety assessment
For cohort I patients, no anesthesia was used when pUDK-
HGF was injected, whereas in cohorts II, III, and IV, C
poisson phenol was used for regional anesthesia before
pUDK-HGF administration because of multiple injection
sites. After injection of pUDK-HGF, no local redness,
swelling, or pain reaction were observed at or near the
injection sites of any patient.
No serious adverse events caused by injection of pUDK-
HGF were found over 3 month follow up. Of the 21 pa-
tients, eight (38.1%) had 20 various adverse events
including abnormal presence of protein in urine, hematuria
or white blood cells in urine, abnormal white blood cell
count, abnormal neutrophil granulocyte percentage,
elevated ALT level, lower extremity purpura, and abnormal
monocyte percentage. Table 3 summarizes adverse events
occurring during the study. However, all these adverse
events were considered to be non-drug related according to
the opinion of the investigators. Dose limiting toxicity did
not occur at the highest dose (16 mg).Pharmacokinetics of pUDK-HGF indicated that no signif-
icant difference in serum HGF protein concentration was
observed among the four cohorts, despite serum HGF
concentrations increasing dramatically in three patients
(Cases 103, 112, 121) at day 8 (Fig. 1 and Table 4).
The plasmid DNA pharmacokinetics gave a below quan-
titative limit (<100 copies/mg gDNA) result for most pa-
tients, except for ﬁve positive results (Table 4). Case 101
showed a relatively high concentration at baseline
(37,592 copies/mg gDNA), and on days 8 (358 copies/mg
gDNA) and 15 (125 copies/mg gDNA). Case 102 also showed
positive results on days 8 (19,447 copies/mg gDNA) and 15
(382 copies/mg gDNA).
Anti-HGF antibody detection showed that no patient
developed antibodies to HGF protein at days 8, 15, 21, and
59.
Pain scale assessment
As shown in Table 5, the mean VAS score decreased
signiﬁcantly from baseline 4.52, to 0.3 (p < .01 versus
baseline) at day 91 after pUDK-HGF treatment. Most pa-
tients showed a decrease in VAS from day 8, and the
improvement was retained throughout the study period.
Eight of 17 patients showed a VAS value decrease of more
than 5 cm. Fourteen patients reported no pain at day 91.
Transcutaneous oximetry pressure results
As shown in Table 6, the mean TcPO2 value on the dorsum of
the foot increased in cohorts I, II, and III, and the mean value
of all cohorts increased from 26.79 at baseline to
34.23 mmHg at day 91. An increase in TcPO2 value
10 mmHg was observed in eight of 17 evaluable patients,
and an increase <10 mmHg was observed in a further two
patients at day 91. The mean TcPO2 value on the posterior
calf increased in cohorts I and III. The mean TcPO2 value of all
cohorts on the posterior calf increased from31.50 at baseline
to 38.39 at day 91. A TcPO2 increase on the posterior calf
>10 mmHg was observed in eight of 17 patients. These re-
sults indicate that pUDK-HGF treatment improves TcPO2
mainly in the dorsum of the foot and the posterior calf.
Table 5. Changes in VAS scores after intramuscular pUDK-HGF injection.
Baseline D8 D15 D21 D28 D59 D91
Cohort I 4.00  1.73 (3) 0.67  1.15 (3) 0.00 (3) 0.00 (3) 0.00 (3) 0.00 (3) 0.00 (3)
Cohort II 5.67  2.94 (6) 3.83  2.64b (6) 3.33  2.66b (6) 3.00  2.45b (6) 2.83  2.40b (6) 1.40  1.34b (5) 1.00  1.73a (5)
Cohort III 5.50  1.97 (6) 4.17  2.14 (6) 3.00  2.10a (6) 2.17  1.47b (6) 1.67  1.75b (6) 0.6  0.94a (5) 0.20  0.45b (5)
Cohort IV 2.92  2.94 (6) 1.00  2.24 (5) 1.00  2.24a (5) 0.80  1.79b (5) 0.60  1.34b (5) 0.00 (4) 0.00 (4)
Data are expressed as mean  SD. (n): No. of patients.
a p < .05.
b p < .01 vs. baseline.
Table 4. HGF protein concentration and pUDK-HGF plasmid copy number in serum after administration of pUDK-HGF.
Days after pUDK-HGF ﬁrst injection
Baseline D8 D15 D21 D59
Cohort I (n) 3 3 3 3 3
HGF (pg/mL) 1410.1  626.9 4559.8  6102.9 1196.7  355.8 1471.8  449.8 1076.8  299.4
HGF (copies/mg gDNA) BQLa
Case 101: 37592
BQL
Case 101: 358
Case 102:19447
BQL
Case 101: 125
Case 102: 382
BQL BQL
Cohort II (n) 6 6 6 6 5
HGF (pg/mL) 2052.5  1420.7 1347.1  809.1 1075.8  410.0 1436.2  954.8 1937.1  2125.4
HGF (copies/mg gDNA) BQL BQL BQL BQL BQL
Cohort III (n) 6 6 6 6 5
HGF (pg/mL) 2424.4  1543.6 10034.0  1044.8 699.1  862.7 816.7  840.3 4536.2  1522.5
HGF(copies/mg gDNA) BQL BQL BQL BQL BQL
Cohort IV (n) 6 5 5 5 4
HGF (pg/mL) 1039.3  748.3 1164.0  701.9 1082.0  928.8 1043.2  818.5 606.1  877.5
HGF (copies/mg gDNA) BQL BQL BQL BQL BQL
Five positive results were shown.
Data are expressed as mean  SD. (n): No. of patients.
a pUDK-HGF plasmid copy number was detected below the limit of 100 copies/mg quantiﬁcation (BQL) in most samples.
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As shown in Table 7, the mean value of ABI increased from
0.40 at baseline to 0.42 at day 91 after treatment in
cohort I, from 0.27 at baseline to 0.43 at day 91 in cohort
II, and from 0.40 to 0.43 in cohort III. However, in cohort
IV, the ABI value was slightly reduced from 0.47 to 0.37.
Seven of 17 patients showed improvement in ABI of more
than 15% compared with the baseline value at day 91.
Even though none of these differences were statistically
signiﬁcant because of the small population, the results
indicate that pUDK-HGF treatment has potential for ABI
improvement.Table 6. Effect of pUDK-HGF injection on transcutaneous oxygen tens
Cohort Days after ﬁrst injection
Baseline (n) D28 (
Dorsum of foot I 21.00  17.09 (3) 34.67
II 27.50  19.96 (6) 47.83
III 15.17  18.99 (6) 29.67
IV 43.50  12.94 (6) 39.00
Posterior calf I 45.00  5.29 (3) 46.33
II 37.67  21.56 (6) 28.67
III 35.50  23.22 (6) 53.50
IV 60.17  13.36 (6) 47.2
Data are expressed as the mean  SD. (n): No. of patients.
a p < .05 vs. baseline.Ulcer and gangrene healing assessment
Ulcer and gangrene healing were evaluated in nine patients,
four with at least one pre-existing ulcer and the other ﬁve
with gangrene (Fig. 2). After pUDK-HGF treatment, two ul-
cers had completely healed, and another two patients had
ulcer size reduction of greater than 25% in long axis diam-
eter. Of the ﬁve patients with gangrene, three showed a
response to pUDK-HGF treatment, with one gangrenous
wound almost healed at day 59 and completely healed at
day 91. The two other gangrenous wounds showed marked
reduction at day 91. Two of the ﬁve patients with gangrene
had no response to pUDK-HGF treatment.ion (TcPO2) in CLI patients.
n) D59 (n) D91 (n)
 19.86 (3) 24.00  24.88 (3) 35.67  19.73 (3)
 55.81 (6) 25.80  25.01 (5) 32.20  27.27 (5)
 20.53 (6)a 45.40  22.51 (5) 30.80  27.40 (5)
 19.52 (5) 36.25  15.44 (4) 38.25  16.80 (4)
 13.87 (3) 28.67  14.47 (3) 51.67  7.51 (3)
 21.44 (6) 30.60  25.19 (5) 28.20  22.55 (5)
 28.68 (6) 29.00  18.97 (5) 48.80  23.86 (5)
0  9.78 (5) 48.50  6.03 (4) 42.50  8.19 (4)
Table 7. Change of ankle brachial index (ABI) in patients after pUDK-HGF injection.
Cohort Days after ﬁrst injection
Baseline (n) D28 (n) D59 (n) D91 (n)
I 0.40  0.23 (3) 0.48  0.23 (3) 0.37  0.15 (3) 0.42  0.22 (2)
II 0.27  0.24 (5) 0.38  0.32 (6) 0.44  0.28 (5) 0.43  0.31 (5)
III 0.40  0.29 (5) 0.42  0.34 (6) 0.50  0.30 (5) 0.43  0.14 (5)
IV 0.47  0.18 (6) 0.47  0.22 (5) 0.48  0.20 (4) 0.37  0.16 (4)
Data are expressed as the mean  SD. (n): No. of patients.
Clinical Safety and Preliminary Efﬁcacy of Plasmid pUDK-HGF 499DISCUSSION
Peripheral arterial disease is a common disorder usually
caused by atherosclerotic changes in the arteries supplying
blood to the lower extremities, resulting in ischemic limb
disease including arteriosclerosis obliterans (ASO), throm-
boangiitis obliterans (Buerger disease, TAO), diabetic arte-
riosclerosis obliterans, and foot ulcers (DASO). The
prevalence of PAD in a Chinese city population aged 60e95
is close to that of the United States, and is reported to be
15.91% (11.77% in males and 19.22% in females).25
Critical limb ischemia (CLI) is a complication of PAD and
remains a major unmet public healthcare need. It causes
claudication, non-healing ulcer, rest pain, and a need for
amputation in some patients. Effective treatment options
for CLI patients involve revascularization by endovascular
approaches or by bypass surgery. Unfortunately, only 50%
of CLI patients can be treated with these techniques and
the beneﬁcial effects are evident in only about 25% of the
patients.26 Therefore, stimulation of collateral vessel for-
mation by gene delivery (gene therapy) seems to be a good
alternative therapy of CLI.
This phase I clinical study was performed to assess the
safety, tolerability, and preliminary efﬁcacy of naked
plasmid pUDK-HGF in patients with CLI. All doses of pUDK-
HGF (4 mg, 8 mg, 12 mg, and 16 mg) were well tolerated byFigure 2. Comparison of ischemic ulcer and gangrene changes in patie
response; NR ¼ no response.the patients. Even in the highest dose cohort (16 mg), with
patients receiving 32 intramuscular injections at one time
(total 64 multiple injections, 0.25 mg/0.5 mL/injection site)
in the calf and/or thigh muscles on days 1 and 15, with no
redness, swelling or pain reaction observed around the in-
jection sites. In total, 20 adverse effects based on clinical
chemistry examinations were reported in all cohorts during
the 3 month follow up period. However, none were
considered to be related to pUDK-HGF administration. Po-
tential side effects, such as hemangioma, cancer, or wors-
ening diabetic retinopathy, were not observed during the
study period.
In general, the serum HGF level remained stable
throughout the 3 month follow up period after pUDK-HGF
administration, although serum HGF concentration in-
creases were observed in three patients (Cases 103, 112,
and 121) at day 8. However, the copy number of exogenous
vector pUDK-HGF was detected to be below the quantita-
tive limit (<100 copies/mg gDNA), implying that the high
serum HGF concentrations of these three patients might
not be induced from injection of exogenous vector. The
DASO, ASO, TAO indications could contribute to the dra-
matic elevation of circulating HGF concentration.27,28 For all
cohorts the level of plasmid in the blood was below 100
copies/mg of genomic DNA and no patient developednts at baseline and Day 91. CR ¼ complete response; PR ¼ partial
500 S. Cui et al.antibodies to HGF protein. These data indicate that intra-
muscular administration of pUDK-HGF is safe and that
transgene expression is limited to the site of injection
without causing systemic change.
The secondary endpoint was preliminary efﬁcacy evalu-
ation. Two signiﬁcant clinical results were observed. pUDK-
HGF injection signiﬁcantly decreased the pain severity and
improved ulcer healing in CLI patients. The mean VAS value
of all the patients decreased signiﬁcantly. Of the 21 pa-
tients, pain had disappeared completely in 14 by their last
visit. Ischemic ulcers healed or reduced markedly by >25%
as a positive response in seven of 10 patients, with two
ulcers and one case of gangrene healing completely.
The present study was different from a previous report
by Gu et al.,17 in that two different plasmids were used,
pUDK-HGF and pCK-HGF-X7, although with similar clinical
trial design. pUDK-HGF is a simple plasmid expressing only
one HGF (728 amino acids) isoform, while pCK-HGF-X7 ex-
presses two isoforms of HGF (723 amino acids and 728
amino acids). The present study indicates that the plasmid
expressing only one isoform appears to be safe and shows
preliminary efﬁcacy with pain reduction and wound healing.
The present study differs from a report by Powell et al. in
the injection strategies used, although both plasmids
expressed a single HGF (728 amino acids) isoform.14 In the
study by Powell et al., the volume and dose per injection
site increased with the increase in total dosage. The plasmid
DNA delivery utilized ultrasound guided injection into the
muscle surrounding occluded tibial vessels. The present
study was designed to increase the number of injection
sites as the total dosage increased. Multiple site injections
were easily done starting from the level of the stenosis and
following the blood vessel distally.
Because of the limitation of small sample size, hemody-
namic parameters such as ABI, TcPO2 appeared to improve
in some cohorts, but variables between the patient groups
were not signiﬁcant statistically. However, the signiﬁcant
pain relief and ulcer healing indicated the preliminary efﬁ-
cacy of intramuscular injection of pUDK-HGF. A larger,
randomized, double blinded, multicentre phase II trial is
being performed in China and will provide more informa-
tion on safety and efﬁcacy.
In conclusion, the present study demonstrates that
intramuscular injection of a simple plasmid pUDK-HGF
expressing only one HGF (728 amino acids) isoform, is
safe, feasible, and potentially provides symptomatic relief
for CLI patients.CONFLICT OF INTEREST
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